<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343140">
  <stage>Registered</stage>
  <submitdate>4/07/2011</submitdate>
  <approvaldate>5/07/2011</approvaldate>
  <actrnumber>ACTRN12611000677909</actrnumber>
  <trial_identification>
    <studytitle>An Australian Study assessing the effects of Avene Thermal Water Spray in patients with recessive dystrophic epidermolysis bullosa</studytitle>
    <scientifictitle>An Australian Study assessing the effects of Avene Thermal Water Spray in patients with recessive dystrophic epidermolysis bullosa</scientifictitle>
    <utrn>Nil</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Epidermolysis Bullosa</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Avene thermal water spray is used to clean all wounds and to clean the skin. This is applied by the patient/carer instead of normal bathing techniques. The frequency will depend on the frequency of bathing and is at the discretion of the patient or carer. Duration of treatment is 6 months.</interventions>
    <comparator>Nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Lifestyle</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>change in size of the selected wounds</outcome>
      <timepoint>6 months: Visitrak machine to measure size of wounds</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>colonisation of wounds: clincial assessment in addition to microbiological methods</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>development of new erosions: clinical assessments</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>improved quality of life: QOLEB qustionnaire at regular intervals (baseline, weeks 12 and 24)</outcome>
      <timepoint>baseline, weeks 12 and 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>decrease in pain scores: which are assessed at regular intervals (baseline, weeks 12 and 24)</outcome>
      <timepoint>baseline, weeks 12 and 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>reduction in antibiotic use: this will be assessed at regular intervals (baseline, weeks 12 and 24)</outcome>
      <timepoint>baseline, weeks 12 and 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>decrease in new wound formation rate compared to previous 3 months: using questionnaires, Vistrak machine and clinical photographs</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>safety and adverse events: eg. infection- assessed clinically as well as microbiological means</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>change in EB severity score: this will be assessed at regular intervals
(baseline, weeks 12 and 24)</outcome>
      <timepoint>baseline, weeks 12 and 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>reduction in hospitalisations: this will be assessed at regular intervals
(baseline, weeks 12 and 24)</outcome>
      <timepoint>baseline, weeks 12 and 24</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosis of RDEB confirmed by IFM/EM</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>unable to provide consent
pregnant; breastfeeding
current participation in another study or trial</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>30/05/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Professor Dedee Murrell</primarysponsorname>
    <primarysponsoraddress>17 Kensington Street
Kogarah
NSW 2217</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Premier Dermatology</fundingname>
      <fundingaddress>17 Kensington Street
Kogarah
NSW 2217</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To determine the efficacy and safety of the Avene Thermal Spring Water (ATSW) in wound healing in patients with recessive dystrophic epidermolysis bullosa. The hypothesis is that the ATSW, instead of bathing, will result in reduced number of infections and improved wound healing.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Dedee Murrell</name>
      <address>17 Kensington Street
Kogarah
NSW 2217</address>
      <phone>+61291132543</phone>
      <fax />
      <email>d.murrell@unsw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Benjamin Daniel</name>
      <address>17 Kensington Street
Kogarah
NSW 2217</address>
      <phone>+61291132543</phone>
      <fax />
      <email>b.daniel@unsw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>